[
  {
    "ts": null,
    "headline": "ResMed Inc. (RMD) Gains Analyst Confidence as Price Targets Rise on Strong Earnings",
    "summary": "ResMed Inc. (NYSE:RMD) is one of the best medical technology stocks to invest in. On January 30, KeyBanc Capital Markets lifted its price target on ResMed Inc. (NYSE:RMD) to $302 from $299 and maintained an Overweight rating. KeyBanc described ResMed’s second-quarter fiscal 2026 results as largely positive and supportive of its overall investment thesis for […]",
    "url": "https://finnhub.io/api/news?id=a63947c81599e06d49cd5e50e268c7664957abd738064de313fcf7fa8340b6aa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771156420,
      "headline": "ResMed Inc. (RMD) Gains Analyst Confidence as Price Targets Rise on Strong Earnings",
      "id": 139105982,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "ResMed Inc. (NYSE:RMD) is one of the best medical technology stocks to invest in. On January 30, KeyBanc Capital Markets lifted its price target on ResMed Inc. (NYSE:RMD) to $302 from $299 and maintained an Overweight rating. KeyBanc described ResMed’s second-quarter fiscal 2026 results as largely positive and supportive of its overall investment thesis for […]",
      "url": "https://finnhub.io/api/news?id=a63947c81599e06d49cd5e50e268c7664957abd738064de313fcf7fa8340b6aa"
    }
  }
]